No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ADMA240719C12500
- 0.15
- -0.15-50.00%
15min DelayClose Jul 11 15:58 ET
0.30High0.15Low
0.16Open0.30Pre Close22 Volume352 Open Interest12.50Strike Price445.00Turnover37.68%IV2.76%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.4119Delta0.5604Gamma61.55Leverage Ratio-0.0177Theta0.0011Rho25.35Eff Leverage0.0072Vega
Intraday
- 5D
- Daily
News
How Is The Market Feeling About ADMA Biologics?
ADMA Biologics's (NYSE:ADMA) short percent of float has fallen 23.1% since its last report. The company recently reported that it has 7.27 million shares sold short, which is 3.23% of all regular
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
ADMA Biologics Is Maintained at Overweight by Cantor Fitzgerald
ADMA Biologics Is Maintained at Overweight by Cantor
ADMA Biologics Price Target Raised to $15.00/Share From $10.00 by Cantor Fitzgerald
ADMA Biologics Price Target Raised to $15.00/Share From $10.00 by Cantor
Adma Biologics (ADMA) Is on the Move, Here's Why the Trend Could Be Sustainable
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $15
Cantor Fitzgerald analyst Kristen Kluska maintains $ADMA Biologics(ADMA.US)$ with a buy rating, and adjusts the target price from $10 to $15.According to TipRanks data, the analyst has a success
Comments
$ADMA Biologics(ADMA.US$
by the end of the year, what price will this stock reach? Any predictions?
by the end of the year, what price will this stock reach? Any predictions?
$ADMA Biologics(ADMA.US$
NEWS
IMPRESSIVE ER
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to m...
NEWS
IMPRESSIVE ER
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to m...
$ADMA Biologics(ADMA.US$
$Coinbase(COIN.US$
$Interactive Brokers(IBKR.US$
$Spotify Technology(SPOT.US$
so as much as it sucks apparently reason doesn't win, and here we are about to ban tiktok I guess? because something somethings china-boogeyman. It seems really foolish to upset millions of voters. let alone young voters. and besides their incredibly progressive leanings. I can't imagine what might backfire there.
That said. Between this and the fake news (like actually misinformation/sens...
$Coinbase(COIN.US$
$Interactive Brokers(IBKR.US$
$Spotify Technology(SPOT.US$
so as much as it sucks apparently reason doesn't win, and here we are about to ban tiktok I guess? because something somethings china-boogeyman. It seems really foolish to upset millions of voters. let alone young voters. and besides their incredibly progressive leanings. I can't imagine what might backfire there.
That said. Between this and the fake news (like actually misinformation/sens...
5
$ADMA Biologics(ADMA.US$
This one looks great. Solid fundamentals and technicals. VMACD shows golden cross, but reg macd still hasn't quite yet. Maybe a small dip coming but... worth it.
This one looks great. Solid fundamentals and technicals. VMACD shows golden cross, but reg macd still hasn't quite yet. Maybe a small dip coming but... worth it.
1
3
Read more